Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: A retrospective analysis

Medical Oncology

Volumn 26, Issue 1, 2009, Pages 32-37

  Kang, Byung Woog ^a   Kim, Tae Won ^a   Lee, Jae Lyun ^a   Ryu, Min Hee ^a   Chang, Heung Moon ^a   Yu, Chang Sik ^a   Kim, Jin Cheon ^a   Kim, Jong Hoon ^a   Kang, Yoon Koo ^a   Lee, Jung Shin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

5 Fluorouracil; Bevacizumab; Colorectal cancer; Irinotecan; Oxaliplatin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; OXALIPLATIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DRUG DERIVATIVE; FOLFOX PROTOCOL; IFL PROTOCOL; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ABSCESS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LUNG EMBOLISM; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERITONITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOSIS; VOMITING; CANCER STAGING; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 65549152542     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9077-8     Document Type: Article

References (26)

1. A Jemal R Siegel E Ward Y Hao J Xu T Murray 2008 Cancer statistics CA Cancer J Clin. 58 71 96
2. S Hr KW Jung YJ Won JG Park 2004 Annual report of the Korea central cancer registry: based on registered data from 139 hospitals Cancer Res Treat. 36 103 14
3. TM Pawlik MA. Choti 2007 Surgical therapy for colorectal metastases to the liver J Gastrointest Surg. 11 1057 77 10.1007/s11605-006-0061-3
4. A Grothey D Sargent RM Goldberg HJ Schmoll 2004 Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol. 22 1209 14 10.1200/JCO.2004.11.037 (Pubitemid 41079833)
5. JA Meyerhardt RJ Mayer 2005 Systemic therapy for colorectal cancer N Engl J Med. 352 476 87 10.1056/NEJMra040958 (Pubitemid 40175974)
6. P Ragnhammar L Hafstrom P Nygren B Glimelius 2001 A systematic overview of chemotherapy effects in colorectal cancer Acta Oncol. 40 282 308 (Pubitemid 32588124)
7. N Ferrara 1999 Molecular and biological properties of vascular endothelial growth factor J Mol Med. 77 527 43 10.1007/s001099900019 (Pubitemid 29426311)
8. MS Gordon 2000 Vascular endothelial growth factor as a target for antiangiogenic therapy J Clin Oncol. 18 Suppl 21 S45 6
9. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med. 350 2335 42 10.1056/NEJMoa032691 (Pubitemid 38702844)
10. BJ Giantonio PJ Catalano NJ Meropol PJ O'Dwyer EP Mitchell SR Alberts 2007 Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol. 25 1539 44 10.1200/JCO.2006.09.6305 (Pubitemid 46733080)
11. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst. 92 205 16 10.1093/jnci/92.3.205
12. DH Lim YS Park BB Park SH Ji J Lee KW Park 2005 Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study Cancer Chemother Pharmacol. 56 10 4 10.1007/s00280-004-0963-2 (Pubitemid 41201750)
13. AS Ardavanis GN Ioannidis GS Orphanos GA Rigatos 2006 Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancer Anticancer Res. 26 1669 72
14. M Gubanski G Naucler A Almerud A Lidestahl PA Lind 2005 Capecitabine as third line therapy in patients with advanced colorectal cancer Acta Oncol. 44 236 9
15. G Rosati A Rosati D Germano G Reggiardo L Manzione 2003 Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study Anticancer Res. 23 2981 5
16. P Pfeiffer D Nielsen M Yilmaz A Iversen C Vejlo BV Jensen 2007 Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil Acta Oncol. 46 697 701 10.1080/02841860601009455 (Pubitemid 46911904)
17. B Vincenzi D Santini C Rabitti R Coppola B Beomonte Zobel L Trodella 2006 Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial Br J Cancer. 94 792 7 10.1038/sj.bjc.6603018
18. DJ Jonker CJ O'Callaghan CS Karapetis JR Zalcberg D Tu HJ Au 2007 Cetuximab for the treatment of colorectal cancer N Engl J Med. 357 2040 8 10.1056/NEJMoa071834 (Pubitemid 350106711)
19. E Van Cutsem M Peeters S Siena Y Humblet A Hendlisz B Neyns 2007 Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol. 25 1658 64 10.1200/JCO.2006.08.1620 (Pubitemid 46797944)
20. D Cunningham Y Humblet S Siena D Khayat H Bleiberg A Santoro 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med. 351 337 45 10.1056/NEJMoa033025 (Pubitemid 38944402)
21. HC Kwon SY Oh S Lee SH Kim HJ Kim 2007 Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study World J Gastroenterol. 13 6231 5 10.3748/wjg.13.6231
22. HX Chen M Mooney M Boron D Vena K Mosby L Grochow 2006 Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301 J Clin Oncol. 24 3354 60 10.1200/JCO.2005.05.1573 (Pubitemid 46638889)
23. RK Jain 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science. 307 58 62 10.1126/science.1104819 (Pubitemid 40093472)
24. HJ Burstein D Spigel K Kindsvogel LM Parker CA Bunnell AH Partridge 2005 Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study Brest Cancer Res Treat. 94 Suppl 1 A4
25. FF Kabbinavar J Schulz M McCleod T Patel JT Hamm JR Hecht 2005 Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol. 23 3697 705 10.1200/JCO.2005.05.112 (Pubitemid 46252464)
26. HC Jeung SY Rha BC Cho NC Yoo JK Roh WJ Roh 2006 A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens Br J Cancer. 95 1637 41 10.1038/sj.bjc.6603468 (Pubitemid 44950788)